ArticleRespiratory medicine case reports2025
Eosinophilia associated with nintedanib therapy.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nintedanib (Ofev) is a widely used antifibrotic agent approved for idiopathic pulmonary fibrosis and other fibrosing interstitial lung diseases, with a known side effect profile that includes gastrointestinal symptoms and hepatotoxicity. However, immune-mediated eosinophilia has not previously been associated with its use. We describe the case of a 69-year-old man recently diagnosed with pulmonary fibrosis who developed marked eosinophilia and transaminitis shortly after initiating treatment with Nintedanib. An extensive evaluation excluded infectious, autoimmune, and alternative drug-related etiologies. Remarkably, both the eosinophilia and liver enzyme abnormalities resolved promptly following the discontinuation of Nintedanib. This case represents, to our knowledge, the first reported instance of Nintedanib-associated eosinophilia, raising the possibility of a delayed hypersensitivity reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.